Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

被引:792
作者
Krejcik, Jakub [1 ,2 ,3 ,4 ]
Casneuf, Tineke [5 ]
Nijhof, Inger S. [1 ]
Verbist, Bie [5 ]
Bald, Jaime [6 ]
Plesner, Torben [2 ,3 ,4 ]
Syed, Khaja [6 ]
Liu, Kevin [7 ]
van de Donk, Niels W. C. J. [1 ]
Weiss, Brendan M. [8 ,9 ]
Ahmadi, Tahamtan [6 ]
Lokhorst, Henk M. [1 ]
Mutis, Tuna [1 ]
Sasser, A. Kate [6 ]
机构
[1] Vrije Univ Amsterdam, Dept Hematol, Med Ctr, Amsterdam, Netherlands
[2] Vejle Hosp, Inst Reg Hlth Sci, Vejle, Denmark
[3] Vejle Hosp, Sect Internal Med, Dept Hematol, Vejle, Denmark
[4] Univ Southern Denmark, Vejle, Denmark
[5] Janssen Res & Dev, Beerse, Belgium
[6] Janssen Res & Dev LLC, 1400 McKean Rd, Spring House, PA 19477 USA
[7] Janssen Res & Dev LLC, Raritan, NJ USA
[8] Univ Penn, Abramson Canc Ctr, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA
[9] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA
关键词
IMPROVED SURVIVAL; PERIPHERAL-BLOOD; SUPPRESSOR-CELLS; TARGETING CD38; ANTIBODY; MONOTHERAPY; GENERATION; MANAGEMENT; SAFETY;
D O I
10.1182/blood-2015-12-687749
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Daratumumab targets CD38-expressing myeloma cells through a variety of immune-mediated mechanisms (complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and antibody-dependent cellular phagocytosis) and direct apoptosis with crosslinking. These mechanisms may also target nonplasma cells that express CD38, which prompted evaluation of daratumumab's effects on CD38-positive immune subpopulations. Peripheral blood (PB) and bone marrow (BM) from patients with relapsed/refractory myeloma from 2 daratumumab monotherapy studies were analyzed before and during therapy and at relapse. Regulatory B cells and myeloid-derived suppressor cells, previously shown to express CD38, were evaluated for immunosuppressive activity and daratumumab sensitivity in the myeloma setting. A novel subpopulation of regulatory T cells (Tregs) expressing CD38 was identified. These Tregs were more immunosuppressive in vitro than CD38-negative Tregs and were reduced in daratumumab-treated patients. In parallel, daratumumab induced robust increases in helper and cytotoxic T-cell absolute counts. In PB and BM, daratumumab induced significant increases in CD8(+):CD4(+) and CD8(+):Treg ratios, and increased memory T cells while decreasing naive T cells. The majority of patients demonstrated these broad T-cell changes, although patients with a partial response or better showed greater maximum effector and helper T-cell increases, elevated antiviral and alloreactive functional responses, and significantly greater increases in T-cell clonality as measured by T-cell receptor (TCR) sequencing. Increased TCR clonality positively correlated with increased CD8(+) PBT-cell counts. Depletion of CD38(+) immunosuppressive cells, which is associated with an increase in T-helper cells, cytotoxic T cells, T-cell functional response, and TCR clonality, represents possible additional mechanisms of action for daratumumab and deserves further exploration.
引用
收藏
页码:384 / 394
页数:11
相关论文
共 36 条
[1]   PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma [J].
Ansell, Stephen M. ;
Lesokhin, Alexander M. ;
Borrello, Ivan ;
Halwani, Ahmad ;
Scott, Emma C. ;
Gutierrez, Martin ;
Schuster, Stephen J. ;
Millenson, Michael M. ;
Cattry, Deepika ;
Freeman, Gordon J. ;
Rodig, Scott J. ;
Chapuy, Bjoern ;
Ligon, Azra H. ;
Zhu, Lili ;
Grosso, Joseph F. ;
Kim, Su Young ;
Timmerman, John M. ;
Shipp, Margaret A. ;
Armand, Philippe .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) :311-319
[2]   Fitting Linear Mixed-Effects Models Using lme4 [J].
Bates, Douglas ;
Maechler, Martin ;
Bolker, Benjamin M. ;
Walker, Steven C. .
JOURNAL OF STATISTICAL SOFTWARE, 2015, 67 (01) :1-48
[3]   Cellular immunotherapy in multiple myeloma: Lessons from preclinical models [J].
Binsfeld, M. ;
Fostier, K. ;
Muller, J. ;
Baron, F. ;
Schots, R. ;
Beguin, Y. ;
Heusschen, R. ;
Caers, J. .
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2014, 1846 (02) :392-404
[4]   Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer [J].
Brahmer, Julie R. ;
Tykodi, Scott S. ;
Chow, Laura Q. M. ;
Hwu, Wen-Jen ;
Topalian, Suzanne L. ;
Hwu, Patrick ;
Drake, Charles G. ;
Camacho, Luis H. ;
Kauh, John ;
Odunsi, Kunle ;
Pitot, Henry C. ;
Hamid, Omid ;
Bhatia, Shailender ;
Martins, Renato ;
Eaton, Keith ;
Chen, Shuming ;
Salay, Theresa M. ;
Alaparthy, Suresh ;
Grosso, Joseph F. ;
Korman, Alan J. ;
Parker, Susan M. ;
Agrawal, Shruti ;
Goldberg, Stacie M. ;
Pardoll, Drew M. ;
Gupta, Ashok ;
Wigginton, Jon M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2455-2465
[5]   Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors [J].
de Weers, Michel ;
Tai, Yu-Tzu ;
van der Veer, Michael S. ;
Bakker, Joost M. ;
Vink, Tom ;
Jacobs, Danielle C. H. ;
Oomen, Lukas A. ;
Peipp, Matthias ;
Valerius, Thomas ;
Slootstra, Jerry W. ;
Mutis, Tuna ;
Bleeker, Wim K. ;
Anderson, Kenneth C. ;
Lokhorst, Henk M. ;
van de Winkel, Jan G. J. ;
Parren, Paul W. H. I. .
JOURNAL OF IMMUNOLOGY, 2011, 186 (03) :1840-1848
[6]   Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression [J].
Deaglio, Silvia ;
Dwyer, Karen M. ;
Gao, Wenda ;
Friedman, David ;
Usheva, Anny ;
Erat, Anna ;
Chen, Jiang-Fan ;
Enjyoji, Keiichii ;
Linden, Joel ;
Oukka, Mohamed ;
Kuchroo, Vijay K. ;
Strom, Terry B. ;
Robson, Simon C. .
JOURNAL OF EXPERIMENTAL MEDICINE, 2007, 204 (06) :1257-1265
[7]   The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies [J].
Dosani, T. ;
Carlsten, M. ;
Maric, I. ;
Landgren, O. .
BLOOD CANCER JOURNAL, 2015, 5 :e306-e306
[8]   CD4+CD25+FoxP3+ regulatory T cells are increased whilst CD3+CD4-CD8-αβTCR+ Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden [J].
Feyler, Sylvia ;
von Lilienfeld-Toal, Marie ;
Jarmin, Sarah ;
Marles, Lee ;
Rawstron, Andy ;
Ashcroft, A. J. ;
Owen, Roger G. ;
Selby, Peter J. ;
Cook, Gordon .
BRITISH JOURNAL OF HAEMATOLOGY, 2009, 144 (05) :686-695
[9]   CD19+CD24hiCD38hi B Cells Maintain Regulatory T Cells While Limiting TH1 and TH17 Differentiation [J].
Flores-Borja, Fabian ;
Bosma, Anneleen ;
Ng, Dorothy ;
Reddy, Venkat ;
Ehrenstein, Michael R. ;
Isenberg, David A. ;
Mauri, Claudia .
SCIENCE TRANSLATIONAL MEDICINE, 2013, 5 (173)
[10]   Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer [J].
Garon, Edward B. ;
Rizvi, Naiyer A. ;
Hui, Rina ;
Leighl, Natasha ;
Balmanoukian, Ani S. ;
Eder, Joseph Paul ;
Patnaik, Amita ;
Aggarwal, Charu ;
Gubens, Matthew ;
Horn, Leora ;
Carcereny, Enric ;
Ahn, Myung-Ju ;
Felip, Enriqueta ;
Lee, Jong-Seok ;
Hellmann, Matthew D. ;
Hamid, Omid ;
Goldman, Jonathan W. ;
Soria, Jean-Charles ;
Dolled-Filhart, Marisa ;
Rutledge, Ruth Z. ;
Zhang, Jin ;
Lunceford, Jared K. ;
Rangwala, Reshma ;
Lubiniecki, Gregory M. ;
Roach, Charlotte ;
Emancipator, Kenneth ;
Gandhi, Leena .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (21) :2018-2028